Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Gastrointestinal 1Breast 1

Conditions

Stomach Neoplasms 1Neoplasms 1Neoplasm Metastasis 1Lung Neoplasms 1Esophageal Neoplasms 1Colonic Neoplasms 1Carcinoma, Hepatocellular 1Breast Neoplasms 1

Interventions

pembrolizumab 18Trastuzumab 7Docetaxel 7Paclitaxel 6Magnetic Resonance Spectroscopy 5Taxes 4Drug Therapy 4Carboplatin 4Specimen Handling 3Psychiatric Rehabilitation 3Polymerase Chain Reaction 3Nivolumab 3Injections 3Fluorouracil 3Fluorodeoxyglucose F18 3Cyclophosphamide 3Cisplatin 3Capecitabine 3Biopsy 3poly ICLC 2fludarabine 2durvalumab 2belinostat 2atezolizumab 2Radiotherapy 2Oxaliplatin 2Leucovorin 2Lapatinib 2Irinotecan 2Interleukin-12 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Esophageal Neoplasms × devimistat × Breast × Clear all
NCT01832857 2016-12-29

Phase 2 Safety, Tolerability and Efficacy Study of CPI-613 in Cancer Patients

Cornerstone Pharmaceuticals

Phase 2 Terminated
7 enrolled
BreastGastrointestinalThoracic

Breast Neoplasms, Colonic Neoplasms, Esophageal Neoplasms, Carcinoma, Hepatocellular, Lung Neoplasms, Neoplasm Metastasis, Neoplasms, Stomach Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡